ReviewFrontiers in nutrition2026
Medicine-food homology substances in cardiovascular disease prevention and management: from mechanisms to clinical evidence and future translation.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the leading global cause of death. "Medicine-food homology" (MFH), a fundamental principle of traditional Chinese medicine (TCM), emphasizes dual nutritional and therapeutic roles of natural substances, thereby attracting increasing attention in disease management. These substances exhibit synergistic effects through multiple targets and signaling pathways, demonstrating significant potential in the prevention, adjuvant therapy, and rehabilitation of CVD. This review presents the mechanisms underlying MFH substances (such as astragalus, codonopsis, and hawthorn) in targeting key pathways related to CVD, and summarizes findings from clinical randomized controlled trials (RCT). This review summarizes MFH substances' role in CVD management, focusing on four core mechanisms (vascular defense, myocardial protection, gut-heart axis regulation, risk factor control) that mediate their multi-targeted, multi-pathway effects (e.g., anti-inflammation via Astragalus, myocardial repair via Ginseng). Clinical evidence confirms MFH substances enhance CVD therapeutic efficacy as adjuvant therapies, with mild adverse reactions, while highlighting the need for further research to advance translational application. Future research should prioritize large-scale multi-center trials, multi-omics integration, and standardized quality control to advance MFH from empirical use to precision medicine, providing new natural product-based strategies for comprehensive CVD prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.